Royalty Report: Cancer, Drugs, Diagnostic – Collection: 328128

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Cancer
  • Drugs
  • Diagnostic
  • Drug Discovery
  • Drug delivery
  • Pharmaceuticals
  • Disease
  • Medical
  • Biotechnology
  • Vaccine
  • Genome
  • Test/Monitoring
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 328128

License Grant
The University grants an exclusive license to their rights in the patent rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Field in the Territory and to develop and perform Licensed Processes solely to the extent necessary to develop Licensed Products and Identified Products in the Field in the Territory.
License Property
The Licensors are owners of patent rights for Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers, and,  Alternatively Spliced mRNA Isoforms As Prognostic Indicators For Metastatic Cancer.
Field of Use
Patents and technology surround the discoveries of alternatively spliced mRNA and protein isoform markers for the diagnosis and prognosis of cancer through the epithelial to mesenchymal transition (“EMT”) in epithelial solid tumor cancers.

Field shall mean use or intended for use in the diagnosis and/or prognosis of cancer, and/or for the medical management of cancer, including without limitation the determination (whether by selection or exclusion) of a particular intervention for the prevention and/or treatment of cancer, in humans, including without limitation the use of specific reagents, kits or diagnostic devices.

IPSCIO Record ID: 330686

License Grant
The agreement grants rights to Licensee to patents and intellectual property, solely to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process into and throughout the Territory for research and development of Companion Diagnostics.

Also included is a grant back If this Licensor desires to develop, manufacture, exploit, import, use, offer for sale or sell any Companion Diagnostic on its own or with or through any Affiliate or Third Party, it will send written notice thereof to Licensee, and, if Licensee chooses not to develop, then Licensor shall be granted any associated rights to do so.

License Property
The licensed technology includes (I) Alternative Splicing Event (ASE) technology based on International Patent Application WO 2012/116248 A1 entitled 'Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers'; and (ii) Technology and know-how stemming.

Companion Diagnostics means any diagnostic product or biomarker arising from work performed by Licensor pursuant to the terms of this Agreement or otherwise derived from or based in whole or in part on Licensees Intellectual Property.

Discovery Product means a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.

Therapeutic Product means an agent with prophylactic or therapeutic activity for the prevention and/or treatment of cancer, developed, in whole or in part, from a Discovery Product and intended to be used, or is used, to treat cancer in humans.

Licensee Patent Rights include
– FGFR1/2 IIIc in NSCLC resistant to erlotinib.
– FGFRviii in glioblastoma.

MIT Patent Rights include
– Alternatively Spliced mRNA lsoforms as Prognostic Indicators for Metastatic Cancer.

Field of Use
Field means the use or intended use in treatment and/or prevention of cancer in humans, and shall include the use of any Licensed Product or Licensed Process in connection with the development of Companion Diagnostics.

Licensees therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer.

IPSCIO Record ID: 369296

License Grant
Licensors hereby grant to Licensee and its affiliates for the term a royalty-bearing, exclusive license to their rights in the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products, Discovery Products and/or Therapeutic Products in the field in the territory and to develop and perform Licensed Processes solely to the extent necessary to develop Licensed Products, Discovery Products, Discovery Products and/or Therapeutic Products in the filed in the territory, subject to any Retained Rights and Mandatory Sublicensing.
License Property
United States Patents and Applications
(A) United States of America Provisional Application Serial No. 61/446,162, Filed February 24, 2011
“Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers”
by Christopher B. Burge, Wu Albert. Cheng, John Condeelis, Frank B. Gertler, Maja Oktay and Irina M. Shapiro
(B) United States of America Provisional Application No. 61/498,387, Filed June 17, 2011
“Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers”
by Christopher B. Burge, Wu Albert. Cheng, John Condeelis, Frank B. Gertler, Maja Oktay and Irina M. Shapiro
(C) United States of America Serial No. 14/000995, Filed August 22, 2013
“Alternatively Spliced mRNA Isoforms As Prognostic Indicators For Metastatic Cancer”
by Christopher B. Burge, Wu Albert. Cheng, John Condeelis, Frank B. Gertler, Maja Oktay and Irina M. Shapiro

Discovery Product shall mean a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.

Screening Assay shall mean the use of Licensed Product or Licensed Process for drug screening and drug discovery for small molecules (e.g., a small organic molecule, nucleic acid, or peptide).

Therapeutic Product shall mean an agent with prophylactic or therapeutic activity for the prevention and/or treatment of cancer, developed, in whole or in part, from a Discovery Product and intended to be used, or is used, to treat cancer in humans.

Field of Use
Field shall mean the use or intended for use in the treatment and/or prevention of cancer in humans.

IPSCIO Record ID: 328126

License Grant
Licensor grants
–   an exclusive right and license in the Field to all of Licensors Intellectual Property, other than the MIT Patent Rights, solely to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process into and throughout the Territory;
–   an exclusive right and sublicense to all of Licensors rights to the MIT Patent Rights under the Therapeutic License Agreement, subject to the Retained Rights, as that term is defined in the Therapeutic License Agreement as of the Effective Date, to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process in the Field for use in the Territory; and
–   a non-exclusive license to all of Licensors Intellectual Property for research and development of Companion Diagnostics.

If at any time Licensee desires to develop, manufacture, exploit, import, use, offer for sale or sell any Companion Diagnostic on its own or with or through any Affiliate or Third Party, it will send written notice thereof to Licensor, and, if Licensor chooses not to develop, then Licensee shall be granted the rights to do so.

License Property
Licensors therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer.

The licensed technology includes (I) Alternative Splicing Event (ASE) technology based on International Patent Application WO 2012/116248 A1 entitled 'Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers'; and (ii) Technology and know-how stemming.

Companion Diagnostics means any diagnostic product or biomarker arising from work performed by Licensee pursuant to the terms of this Agreement or otherwise derived from or based in whole or in part on Licensors Intellectual Property.

Discovery Product means a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.

Licensor Patent Rights include
– FGFR1/2 IIIc in NSCLC resistant to erlotinib.
– FGFRviii in glioblastoma.

MIT Patent Rights include
– Alternatively Spliced mRNA lsoforms as Prognostic Indicators for Metastatic Cancer.

Field of Use
Field means the use or intended use in treatment and/or prevention of cancer in humans, and shall include the use of any Licensed Product or Licensed Process in connection with the development of Companion Diagnostics.

Licensee is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies.

IPSCIO Record ID: 4559

License Grant
The Licensor will be assigning all of its right, title and interest in this MOU to the Licensee. The Assets shall include an assignment and/or sublicense of all rights and obligations under the Licensor's existing Therapeutic License Agreement with the Massachusetts Institute of Technology and its David H. Koch Institute for Integrative Cancer Research at MIT and its Department of Biology, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center as of December 7, 2013, the “Alternative Splicing Therapeutic License Agreement”.
License Property
Licensed Technology shall include Alternative Splicing Event technology based on International Patent Application WO 2012/116248 A1 entitled 'Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers'.
Field of Use
Field of Use Make, use and sell all therapeutic compounds, all ASE (Alternative Splicing Event) targets for therapeutic use and drug discovery in all fields, worldwide; and make and use all Companion Diagnostics developed for ASE targets in all fields, worldwide.

IPSCIO Record ID: 4557

License Grant
The Licensor hereby grants the Licensee a royalty-bearing license under the rights in the Tangible Property to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Field in the Territory and to perform Licensed Services in the Field in the Territory.

Licensee shall have the right to grant a Sublicense to the Tangible Property.

License Property
United States of America Patent No. 8603738.
Field of Use
Field shall mean products and services for diagnostic use in humans.

The Licensee develops and commercializes novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis – cancer that spreads from a primary tumor through the bloodstream to other areas of the body.

IPSCIO Record ID: 263930

License Grant
The University grants a license under the patent rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed products in the Field in the Territory and to develop and perform Licensed processes in the Field in the Territory.
License Property
The licensed patents are titled
–Method for Screening Libraries of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity Using Microwells for the Spatial Separation of Cells Producing the Enzymes;
–Method for Diagnosing Allergic Reactions;
–Method for Detecting Active and Latent Virally Infected Cells;
–Method for Assessing Cytotoxicity of Single Cells;
–Composition of an Array of Microwells with an Integrated Microfluidic System; and,
–Screening Assays and Methods.

The Apparatus Product shall mean a Licensed Product that is a microarray comprising microwells.

The Diagnostic Product shall mean a Licensed Product or Discovered Product that is used or intended for use  in the diagnosis and/or prognosis of diseases or conditions, and/or for the medical management of disease or conditions, including without limitation the determination of a particular intervention for the prevention and/or treatment of disease, in humans, including without limitation application specific reagents and kits.

The Therapeutic Product shall mean a Licensed Product or Discovered Product that is used or intended for use in the treatment and/or prevention of human disease, including, without limitation, therapeutic and prophylactic vaccines.

The Veterinary product shall mean a Licensed product or Discovered product that is used or intended for use in the diagnosis and/or prognosis of disease in non-human animals, and/or the determination of a particular intervention for the prevention and/or treatment of disease, including without limitation application specific reagents and kits, and/or the treatment and/or prevention of disease in non-human animals, including without limitation therapeutic and prophylactic vaccines.

Field of Use
The Field of use shall mean all fields.

IPSCIO Record ID: 328124

License Grant
The University grants a worldwide, exclusive license to Licensor’s rights in the Agreement Patents, along with the right by Licensee only to grant sublicenses, to make, have made, use, have used, provide, import, have imported, offer to sell, sell and have sold Licensed Products.
License Property
Licensor is the owner of a patent application related to isolation, gene expression, and chemotherapeutic resistance of motile cancer cells and human invasion signature for prognosis of metastatic risk.

The patents include Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells, and, Human Invasion Signature For Prognosis Of Metastatic Risk.

The intellectual property covered by the Second License Agreement are summarized as follows

1.
U.S. Patent Application No. 11/659,514 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells”

2.
Canadian Patent Application No. 2,576,702 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells”

3.
European Patent Application No. 05807467.5 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells”

4.
U.S. Provisional Patent Application (pending) entitled “Human Invasion Signature For Prognosis Of Metastatic Risk”

The intellectual property covered by the Third License Agreement are summarized as follows

1.
U.S. Patent Application No. 12/998,237 (based on PCT International Patent Application No. PCT/2009/005851) entitled “An In Vivo Quantitative Screening Test For Anti-Metastasis Treatment Efficacy”

Field of Use
The Diagnostic Field means products and services for diagnostic use.

The Therapeutic Field means products and services for therapeutic use.

IPSCIO Record ID: 344534

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

Licensor grants a non- exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
Licensor owns, controls and/or has the right to sublicense the Licensed Subject Matter which is the licensed patents and technology.

The patents include
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
Compositions and Methods for the Diagnosis and Therapy of BCL2-Associated Cancers
MicroRNA Based Methods and Compositions for the Diagnosis and Treatment of Colon Related Diseases
Ultraconserved Regions Encoding ncRNAs
Methods for Identifying Fragile Histidine Triad (Fhit) Interaction and Uses Thereof
Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155
Materials and Methods Related to MicroRNA-21. Mismatch Repair, And Colorectal Cancer
Mutator activity induced by microRNA-155 (miR-155) Links Inflammation and Cancer
Methods and Compositions Related to miR-21 & miR-29a and Cancer Metastasis
Mechanism of NSAID Chemoprevention in Colorectal Cancer

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
Exclusive Field of Use is for the diagnosis, prognosis and therapy/treatment of colon cancer.

IPSCIO Record ID: 299285

License Grant
University grants an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use and sell joint licensed products.
License Property
The University jointly owns and is a joint proprietor of certain intellectual property relating to the human BRCA-2 breast cancer gene.
Field of Use
The field of use means any and all applications and uses of the BRCA-2 breast cancer gene, including but not limited to all diagnostic and therapeutic applications.

IPSCIO Record ID: 4690

License Grant
The Licensee agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology.
License Property
The non-exclusive license is to a worldwide portfolio of patents and patent applications directed to Diagnosis and Prognosis of Breast Cancer Patients (e.g., claiming priority to U.S. Provisional Patent Nos. 60/298918 and/or 60/380710) in the fields of research, diagnosis, prognosis and/or prediction of therapeutic outcome or risk for humans or animals in the area of oncology.

IPSCIO Record ID: 372423

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

University grants a non-exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
The patents include
– MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers;
– Compositions and Methods for the Diagnosis and Therapy of BCL2-Associated Cancers;
– MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders;
– Ultraconserved Regions Encoding ncRNAs; and,
– Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155.

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
The Exclusive Field of Use for the diagnosis, prognosis and therapy/treatment of prostate cancer.

IPSCIO Record ID: 3479

License Grant
The Licensor grants the Licensee a world-wide exclusive license to materials and methods for use in the diagnosis and treatment of metastatic spread of solid tumor cancers.
License Property
Licensors have developed certain hybridoma cell lines that produce and uses thereof in diagnosis, prognosis and treatment of tumors.

U.S. Provisional Patent Application No. 61/276,263, entitled 'Tumor Microenvironment of Metastasis (TMEM)

Cell Line means a hybridoma cell line that produces Anti-pan Mena murine monoclonal antibodies.

Materials means anti-pan Mena murine monoclonal antibodies produced by the Cell Line.

Diagnostic Field means products and services for diagnostic use.
Therapeutic Field means products and services for therapeutic use.

U.S. Patent Application No. 12/462,324, entitled 'Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors'

U.S. Continuation-in-part of PCT/US08/1343, entitled 'Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors'

In return, the Licensee has agreed to grant equity to Licensors, to reimburse Licensors patent expenses thus far incurred, to pay all future patent expenses, pay a royalty on any sales of product using Licensed technology, as well as certain minimum royalties and milestone payments.

Field of Use
The Licensee was formed to allow cancer patients to benefit from the latest discoveries in how cancer spreads to other organs in the body. The Licensee's goal is to become an industry leader in the emerging field of personalized cancer therapy.

IPSCIO Record ID: 344535

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

Licensor grants a non- exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
Licensor owns, controls and/or has the right to sublicense the Licensed Subject Matter, meaningthe patents and technology.

Patents include
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers,
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer,
Material and Methods Useful for Affecting Tumor Cell Growth, Migration, and Invasion,
Ultraconserved Regions Encoding ncRNAs,
Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155,
Methods for Reverting Methylation by Targeting DNMT3A and DNMT3B,
Methods of Identifying Fragile Histidine Triad (FHIT) Interaction and Uses Thereof,
Methods and Compositions Related to miR-21 and miR-29a, Exosome Inhibition and Cancer Mestastsis,
miRNAs Useful to Reduce Lung Cancer Turmorigenesis and Chemotherpay Resistance and Related Compositions and Methods,
Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer, and,
Use of miR-494 to Modulate TRAIL-induced Apoptosis through BIM Down-regulation.

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
The Exclusive Field of use is for the diagnosis, prognosis and therapy/treatment of lung cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.